Böblingen/Lódz – German pharmaceutical company Wörwag Pharma GmbH & Co. KG announces the acquisition of Sensilab, contract manufacturer and development service provider of pharmaceuticals, in Lódz, Poland. For the first time in the 50-year history, the family-owned company is investing in its own production facility - a decisive milestone for future growth.
"With the purchase of this production company, we are laying an important foundation stone for our ambitious growth targets," said Managing Director and CFO Gerhard Mayer. "Together with the Polish management, we will develop the site into a center of excellence for oral dosage forms for the Wörwag Pharma group."
Wörwag Pharma is investing primarily in the expansion of its global product portfolio and the development of new markets.
With the acquisition of Sensilab, the company is securing the necessary production capacities in addition to its existing partnerships with suppliers. On the other hand, Wörwag will be able to guarantee a reliable supply chain and provide its customers with continuous access to high-quality products.
The modern building complex for production and development offers the opportunity to create capacity for further growth. The location is logistically favorable for supplying the core markets in Eastern Europe. In addition, Sensilab brings further expertise to the company to expand the product portfolio by developing its own innovations.
About Sensilab
Sensilab is a contract manufacturer and development service provider for tablets, powders, granules and hard capsules. The production site in Konstantynów Łódzki in the greater Lodz area, Poland, employs 180 people who supply customers mainly in the European region. Sensilab most recently belonged to the Polish USP group of companies.
